Last reviewed · How we verify
SABER-Bupivacaine
SABER-Bupivacaine is a sustained-release formulation of bupivacaine, a local anesthetic that blocks nerve impulses.
SABER-Bupivacaine is a sustained-release formulation of bupivacaine, a local anesthetic that blocks nerve impulses. Used for Postoperative pain management.
At a glance
| Generic name | SABER-Bupivacaine |
|---|---|
| Also known as | POSIMIR® bupivacaine solution |
| Sponsor | Durect |
| Drug class | Local anesthetic |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
By blocking nerve impulses, SABER-Bupivacaine provides prolonged pain relief. This is achieved through the sustained release of bupivacaine from a biodegradable polymer matrix.
Approved indications
- Postoperative pain management
Common side effects
- Nausea
- Vomiting
- Dizziness
- Headache
- Paresthesia
Key clinical trials
- An Extension Trial to Evaluate Long-term Safety of SABER™-Bupivacaine for Pain Following Shoulder Surgery
- Trial of Extended Release Bupivacaine for Pain Relief After Surgery (PHASE3)
- An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery (PHASE2)
- Bupivacaine Effectiveness and Safety in SABER® Trial (PHASE3)
- A Safety and Effectiveness Study of SABER®-Bupivacaine for Pain Following Shoulder Surgery (PHASE2)
- An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Undergoing Hysterectomy (PHASE2)
- A Safety and Efficacy Study of SABER®-Bupivacaine for Pain Following Hernia Repair (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SABER-Bupivacaine CI brief — competitive landscape report
- SABER-Bupivacaine updates RSS · CI watch RSS
- Durect portfolio CI